References of "Petrossians, Patrick"
     in
Bookmark and Share    
See detailA multicenter collaborative study to measure the prevalence of pituitary disease : methodology and preliminary findings
Tikhomirova, M.; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 15th Meeting of the Belgian Endocrine Society : Bruxelles, 26 novembre 2005 (2005, November)

Detailed reference viewed: 8 (0 ULg)
See detailMale Hypogonadism caused by isolated luteinizing hormone deficiency
Daly, Adrian ULg; Salvi, R.; Petrossians, Patrick ULg et al

in 37th International symposium - GH and Growth Factors in Endocrinology and Metabolism (Athènes Symposium) (2005)

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailGross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
Petrossians, Patrick ULg; Borges-Martins, L.; Espinoza, C. et al

in European Journal of Endocrinology (2005), 152(1), 61-66

Introduction: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60 ... [more ▼]

Introduction: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60% of cases. The impact of tumor debulking on subsequent control of acromegaly with SSAs has not been studied previously. Methods: We studied retrospectively the response to SSA therapy in acromegalic patients before and after incomplete surgical tumor excision. A case review identified 24 acromegalic patients who had received SSA therapy for 1 month before and after gross total resection or debulking of adenomas. No patient received radiotherapy or combination treatment with SSAs and dopamine agonists during the study. GH and IGF-I responses to SSAs were recorded pre- and postoperatively. Postoperative SSA therapy was begun after a washout period of 1–3 months to assess the hormonal effects of the surgery alone. Results: Before preoperative SSA treatment, 24/24 (100%) patients had elevated GH levels and IGF-I levels were elevated in 19/21 (90.5%) patients with recorded values. During preoperative SSA treatment, GH and IGF-I levels were normalized in 7/24 (29.2%) and 11/24 (45.8%) patients respectively. Following postoperative washout, GH was controlled in only 3/24 (12.5%) patients, while IGF-I was controlled in 8/19 (42.1%) patients with available data. During the second SSA treatment period, normal GH levels were seen in 13/24 (54.2%) patients, while IGF-I control was noted in 18/23 (78.3%). Conclusion: Gross total tumor resection or debulking increases the likelihood of achieving biochemical disease control with SSAs in acromegalic patients with adenomas that were not amenable to complete surgical resection and in whom primary SSA therapy was unable to achieve good biochemical control. [less ▲]

Detailed reference viewed: 49 (5 ULg)
Full Text
Peer Reviewed
See detailAn overview of the epidemiology and genetics of acromegaly.
Daly, Adrian ULg; Petrossians, Patrick ULg; Beckers, Albert ULg

in Journal of Endocrinological Investigation (2005), 28(11 Suppl International), 67-69

Historical data indicate that pituitary tumors represent 10% of intracranial tumors, while adenomas are noted in approximately 14-23% of normal subjects on autopsy or magnetic resonance imaging (MRI ... [more ▼]

Historical data indicate that pituitary tumors represent 10% of intracranial tumors, while adenomas are noted in approximately 14-23% of normal subjects on autopsy or magnetic resonance imaging (MRI). About 2.5% of these tumors stain positive for GH in histopathologic studies. In contrast, the prevalence of clinically diagnosed acromegaly is lower at 36-69 per million population. Ongoing studies indicate that the actual prevalence of acromegaly in the community may be higher than previous epidemiologic data suggest. Acromegaly can occur both sporadically and in the setting of familial conditions, such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Isolated familial somatotropinoma has been described and newer data suggest that acromegaly may also occur in non-MEN1/CNC families in combination with other pituitary tumor phenotypes. [less ▲]

Detailed reference viewed: 62 (16 ULg)
Full Text
See detailControl of tumor size and hormonal hypersecretion in acromegaly : a large single-center experience
Daly, Adrian ULg; Tikhomirova, M.; Petrossians, Patrick ULg et al

in European Congress of Endocrinology - Abstract book (2005)

Detailed reference viewed: 14 (1 ULg)
See detailA multicenter collaborative study to measure the prevalence of pituitary disease : methodology and preliminary findings
Daly, Adrian ULg; Petrossians, Patrick ULg; Murat, A. et al

in 9th International Pituitary Congress - Abstract book (2005)

Detailed reference viewed: 8 (0 ULg)
See detailDiagnosis of active acromegaly : is it time to amend the consensus of opinions?
Beckers, Albert ULg; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in International Novartis Workshop - somatostatin and its natural and synthetic analogues - Update from basic to clinical aspects - Abstract book (2005)

Detailed reference viewed: 5 (0 ULg)
See detailApproaching the true prevalence of pituitary tumors
Beckers, Albert ULg; Adam, C.; Ciccarelli, A. et al

in ENEA congress : Napoli, April 2004 (2004, April)

Detailed reference viewed: 11 (0 ULg)
See detailSurgical debulking of GH secreting pituitary adenomas improves GH control of acromegaly by somatostatin analogs
Beckers, Albert ULg; Petrossians, Patrick ULg; Borges Martins, L. et al

in ENEA congress : Napoli, April 2004 (2004, April)

Detailed reference viewed: 14 (0 ULg)
See detailGonadotropin secreting tumors
Beckers, Albert ULg; Ciccarelli, A.; Valdes Socin, Hernan Gonzalo ULg et al

in The Encyclopedia of Endocrinology and Endocrine Diseases (2004)

Detailed reference viewed: 27 (1 ULg)
See detailApproaching the true prevalence of pituitary tumors
Beckers, Albert ULg; Ciccarelli, A.; Daly, Adrian ULg et al

in 12th International Congress of Endocrinology - Abstract book (2004)

Detailed reference viewed: 6 (0 ULg)
See detailUne approche de la vraie prévalence des tumeurs hypophysaires
Beckers, Albert ULg; Ciccarelli, A.; Daly, Adrian ULg et al

in XXIème Congrès de la Société Française d'Endocrinologie - Abstract book (2004)

Detailed reference viewed: 9 (3 ULg)
See detailLa réduction chirurgicale de la masse tumorale des adénomes hypophysaires améliore le contrôle médical de l'acromégalie par les analogues de la Somatostatine
Petrossians, Patrick ULg; Borges-Martins, L.; Espinoza, C. et al

in XXIème Congrès de la Société Française d'Endocrinologie - Abstract book (2004)

Detailed reference viewed: 34 (2 ULg)
Full Text
Peer Reviewed
See detailExtensive inflammatory pseudotumor of the pituitary.
Hansen, Isabelle ULg; Petrossians, Patrick ULg; Thiry, Albert ULg et al

in Journal of Clinical Endocrinology and Metabolism (2001), 86(10), 4603-4610

A 40-yr-old female presented with an extensive lesion of the sellar area and the sphenoid sinus, spreading to the optic nerves and associated with pachymeningitis. Histological findings were consistent ... [more ▼]

A 40-yr-old female presented with an extensive lesion of the sellar area and the sphenoid sinus, spreading to the optic nerves and associated with pachymeningitis. Histological findings were consistent with an inflammatory pseudotumor, and steroid treatment allowed the disappearance of all the lesions. Inflammatory pseudotumors of the pituitary are very rare. This case appears unique with regard to the extension of the lesions and the dramatic response to medical treatment. The differential diagnosis of inflammatory lesions of the pituitary is difficult. It relies mainly on histological analysis and includes sarcoidosis, Wegener's granulomatosis, histiocytosis (Langerhans, Rosai-Dorfman, and Erdheim-Chester diseases) and lymphocytic hypophysitis. [less ▲]

Detailed reference viewed: 32 (1 ULg)
Full Text
Peer Reviewed
See detailACTH silent adenoma shrinking under cabergoline.
Petrossians, Patrick ULg; Ronci, N.; Valdes Socin, Hernan Gonzalo ULg et al

in European Journal of Endocrinology (2001), 144(1), 51-57

OBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non ... [more ▼]

OBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas. DESIGN: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a 77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the original tumor were performed. METHODS: The original tumor from the patient was studied by in situ hybridization and dopamine D2 receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas from patients with Cushing's disease. RESULTS: The D2 receptor mRNA signal of the reported case was intense and of the same order of magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was twice that of control corticotroph adenomas and was close to that observed in prolactinomas. CONCLUSIONS: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas. These results suggest that therapeutic trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more generally, non-functioning pituitary adenomas. [less ▲]

Detailed reference viewed: 30 (1 ULg)
Peer Reviewed
See detailLes hyperparathyroidies primaires: étiologies, diagnostic et traitement.
Janssens, L.; Verbeke, V.; Petrossians, Patrick ULg et al

in Revue Médicale de Liège (2000), 55(11), 977-985

L'hyperparathyroïdie primaire est une maladie trop souvent méconnue. Son incidence est estimée à 28/100.000, soit environ 2.800 nouveaux cas par an en Belgique. La fréquence de l'hyperparathyroïdie ... [more ▼]

L'hyperparathyroïdie primaire est une maladie trop souvent méconnue. Son incidence est estimée à 28/100.000, soit environ 2.800 nouveaux cas par an en Belgique. La fréquence de l'hyperparathyroïdie augmente avec l'âge. En effet, 50 % des cas sont rencontrés après l'âge de 70 ans et 3 à 4 % des femmes au-delà de 70 ans sont touchées par l'affection. Cette affection peut être sporadique ou survenir dans un cadre étiologique plus complexe tel que les polyendocrinopathies ou la neurofibromatose. L'attention vers ce diagnostic doit être attirée par une symptomatologie, souvent bâtarde, de fatigue (parfois isolée), de polyurie, de polydipsie, d'hypertension artérielle ou la présence de lithiases rénales. Lorsque le diagnostic d'hyperparathyroïdie est renteu, il convient de localiser la ou les glande(s) pathologique(s) et de définir le contexte étiologique qui pourra déterminer le choix thérapeutique le plus approprié. Une étude biologique simple sera réalisée devant toute suspicion d'hyperparathyroïdie. Dans certains cas, le diagnostic sera aidé par la réalisation d'un test de surcharge calcique qui peut permettre de confirmer l'hyperparathyroïdie et d'apprécier son degré d'autonomisation. [less ▲]

Detailed reference viewed: 76 (3 ULg)
Full Text
Peer Reviewed
See detailMalignant prolactinoma discovered by D2 receptor imaging.
Petrossians, Patrick ULg; de Herder, W.; Kwekkeboom, D. et al

in Journal of Clinical Endocrinology and Metabolism (2000), 85(1), 398-401

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailCabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst, Johan; Abs, Roger; Maiter, Dominique et al

in Journal of Clinical Endocrinology and Metabolism (1999), 84(7), 2518-22

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number ... [more ▼]

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. We also evaluated the effects of cabergoline in a large subgroup of patients with bromocriptine intolerance or -resistance. We retrospectively reviewed the files of 455 patients (102 males and 353 females) with pathological hyperprolactinemia treated with cabergoline in 9 Belgian centers. Among these patients, 41% had a microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperprolactinemia; and 1%, an empty sella. The median pretreatment serum PRL level was 124 microg/L (range, 16-26,250 microg/L). A subgroup of 292 patients had previously been treated with bromocriptine, of which 140 showed bromocriptine intolerance and 58 showed bromocriptine resistance. Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Pretreatment visual field abnormalities normalized in 70% of patients, and tumor shrinkage was seen in 67% of cases. Side effects were noted in 13% of patients, but only 3.9% discontinued therapy because of side effects. The median dose of cabergoline at the start of therapy was 1.0 mg/week but could be reduced to 0.5 mg/week once control was achieved. Patients with a macroprolactinoma needed a higher median cabergoline dose, compared with those with idiopathic hyperprolactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week, although a large overlap existed between these groups. Twenty-seven women treated with cabergoline became pregnant, and 25 delivered a healthy child. One patient had an intended abortion and another a miscarriage. In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. We confirmed, in a large-scale retrospective study, the high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia, leaving few patients with unacceptable side effects or inadequate clinical response. Patients with idiopathic hyperprolactinemia or a microprolactinoma, on average, needed only half the dose of cabergoline as those with macroprolactinomas and have a higher chance of obtaining PRL normalization. Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy. [less ▲]

Detailed reference viewed: 60 (2 ULg)
Full Text
Peer Reviewed
See detailFamilial Acromegaly: Case Report and Review of the Literature
Verloes, Alain ULg; Stevenaert, Achille ULg; Teh, B. T. et al

in Pituitary (1999), 1(3-4), 273-277

Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been ... [more ▼]

Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of action of the gene responsible of familial acromegaly, but no data have been published to sustain or reject this hypothesis. [less ▲]

Detailed reference viewed: 30 (1 ULg)